Coeptis Therapeutics Enters into Exclusive Option Agreement with University of Pittsburgh for Rights to CAR-T Technologies Designed to Target Multiple Cancer Indications, Including Hematologic and Solid Tumors
Stock Information for Coeptis Therapeutics Holdings Inc.
Loading
Please wait while we load your information from QuoteMedia.